Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07554573 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)

Study acronym: ABCD RT
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 30, 2026 to Jan 30, 2027 Eligibility criteria expanded, about 23 words · Secondary endpoints: details revised at 2 of 10 entries · Study description expanded, about 10 words Show 3 more changesShow less
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 2 of 10 entries
    • Study description expanded, about 10 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
NRG Oncology
67 trials monitored
See 5 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
NRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR) compared to those treated with RT (Cohort A).
Trial Details
NCT Number NCT07554573
Lead Sponsor NRG Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer
Enrollment 5,270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov